Cargando…

Drug use in Canadian patients with trauma after cannabis legalization

BACKGROUND: The federal Cannabis Act came into force on Oct. 17, 2018, in Canada, making Canada only the second country in the world to legalize the cultivation, acquisition, possession and consumption of cannabis and its by-products. This provided a unique opportunity to evaluate the impact of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Ball, Ian M., Priestap, Fran, Parry, Neil, Pace, Jacob, Vogt, Kelly N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: CMA Joule Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410467/
https://www.ncbi.nlm.nih.gov/pubmed/34296708
http://dx.doi.org/10.1503/cjs.000620
_version_ 1783747123044417536
author Ball, Ian M.
Priestap, Fran
Parry, Neil
Pace, Jacob
Vogt, Kelly N.
author_facet Ball, Ian M.
Priestap, Fran
Parry, Neil
Pace, Jacob
Vogt, Kelly N.
author_sort Ball, Ian M.
collection PubMed
description BACKGROUND: The federal Cannabis Act came into force on Oct. 17, 2018, in Canada, making Canada only the second country in the world to legalize the cultivation, acquisition, possession and consumption of cannabis and its by-products. This provided a unique opportunity to evaluate the impact of this legislation on drug-related trauma. METHODS: We performed a prospective observational study on the use of cannabis and other illicit drugs in the trauma population at a lead Canadian trauma centre in London, Ontario, in the 3 months before (July 1 to Sept. 30, 2018) and 3 months after (Nov. 1, 2018, to Jan. 31, 2019) the legalization of cannabis in Canada. We defined cannabis use as a positive cannabinoid screen result at the time of assessment by the trauma team. We also screened for opioids, amphetamines and cocaine. RESULTS: A total of 210 patients were assessed by our trauma service between July 1 and Sept. 30, 2018, and 141 patients were assessed between Nov. 1, 2018, and Jan. 31, 2019. Motor vehicle collisions were the most common cause of trauma both before (101 [48.1%]) and after (67 [47.5%]) legalization. The mean Injury Severity Score was 17.6 (standard deviation [SD] 13.0) and 19.7 (SD 14.8), respectively. Drug screens were done in 88 patients (41.9%) assessed before legalization and 99 patients (70.2%) assessed after legalization. There was no difference in the rate of positive cannabinoid screen results before and after legalization (22 [25%] v. 22 [22%]). There was a trend toward higher rates of positive cannabinoid screen results (2/10 [20%] v. 5/8 [62%]) and positive toxicology screen results (5/10 [50%] v. 6/8 [75%]) after legalization among patients with penetrating trauma, but our sample was too small to achieve statistical significance. CONCLUSION: We found no difference in the rates of positive cannabinoid screen results among patients assessed at our trauma centre in the 3 months before and the 3 months after legalization of cannabis; however, there was a trend toward an increase in the rates of positive results of toxicology screens and cannabinoid screens among those with penetrating trauma. These preliminary single-centre data showing no increased rates of cannabis use in patients with trauma after legalization are reassuring.
format Online
Article
Text
id pubmed-8410467
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher CMA Joule Inc.
record_format MEDLINE/PubMed
spelling pubmed-84104672021-09-03 Drug use in Canadian patients with trauma after cannabis legalization Ball, Ian M. Priestap, Fran Parry, Neil Pace, Jacob Vogt, Kelly N. Can J Surg Research BACKGROUND: The federal Cannabis Act came into force on Oct. 17, 2018, in Canada, making Canada only the second country in the world to legalize the cultivation, acquisition, possession and consumption of cannabis and its by-products. This provided a unique opportunity to evaluate the impact of this legislation on drug-related trauma. METHODS: We performed a prospective observational study on the use of cannabis and other illicit drugs in the trauma population at a lead Canadian trauma centre in London, Ontario, in the 3 months before (July 1 to Sept. 30, 2018) and 3 months after (Nov. 1, 2018, to Jan. 31, 2019) the legalization of cannabis in Canada. We defined cannabis use as a positive cannabinoid screen result at the time of assessment by the trauma team. We also screened for opioids, amphetamines and cocaine. RESULTS: A total of 210 patients were assessed by our trauma service between July 1 and Sept. 30, 2018, and 141 patients were assessed between Nov. 1, 2018, and Jan. 31, 2019. Motor vehicle collisions were the most common cause of trauma both before (101 [48.1%]) and after (67 [47.5%]) legalization. The mean Injury Severity Score was 17.6 (standard deviation [SD] 13.0) and 19.7 (SD 14.8), respectively. Drug screens were done in 88 patients (41.9%) assessed before legalization and 99 patients (70.2%) assessed after legalization. There was no difference in the rate of positive cannabinoid screen results before and after legalization (22 [25%] v. 22 [22%]). There was a trend toward higher rates of positive cannabinoid screen results (2/10 [20%] v. 5/8 [62%]) and positive toxicology screen results (5/10 [50%] v. 6/8 [75%]) after legalization among patients with penetrating trauma, but our sample was too small to achieve statistical significance. CONCLUSION: We found no difference in the rates of positive cannabinoid screen results among patients assessed at our trauma centre in the 3 months before and the 3 months after legalization of cannabis; however, there was a trend toward an increase in the rates of positive results of toxicology screens and cannabinoid screens among those with penetrating trauma. These preliminary single-centre data showing no increased rates of cannabis use in patients with trauma after legalization are reassuring. CMA Joule Inc. 2021-07-23 /pmc/articles/PMC8410467/ /pubmed/34296708 http://dx.doi.org/10.1503/cjs.000620 Text en © 2021 CMA Joule Inc. or its licensors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Research
Ball, Ian M.
Priestap, Fran
Parry, Neil
Pace, Jacob
Vogt, Kelly N.
Drug use in Canadian patients with trauma after cannabis legalization
title Drug use in Canadian patients with trauma after cannabis legalization
title_full Drug use in Canadian patients with trauma after cannabis legalization
title_fullStr Drug use in Canadian patients with trauma after cannabis legalization
title_full_unstemmed Drug use in Canadian patients with trauma after cannabis legalization
title_short Drug use in Canadian patients with trauma after cannabis legalization
title_sort drug use in canadian patients with trauma after cannabis legalization
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410467/
https://www.ncbi.nlm.nih.gov/pubmed/34296708
http://dx.doi.org/10.1503/cjs.000620
work_keys_str_mv AT ballianm druguseincanadianpatientswithtraumaaftercannabislegalization
AT priestapfran druguseincanadianpatientswithtraumaaftercannabislegalization
AT parryneil druguseincanadianpatientswithtraumaaftercannabislegalization
AT pacejacob druguseincanadianpatientswithtraumaaftercannabislegalization
AT vogtkellyn druguseincanadianpatientswithtraumaaftercannabislegalization